Multivariate analysis of donor and recipient combinatorial CCR5 genotype
| Outcome . | Overall P§ . | D-R group 2* vs D-R group 1† . | D-R group 3‡ vs D-R group 1 . | D-R group 3‡ vs D-R group 2 . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% confidence interval . | P . | HR . | 95% confidence interval . | P . | HR . | 95% confidence interval . | P . | ||
| Overall survival | .007 | 0.91 | (0.73-1.12) | .371 | 1.41 | (1.114-1.783) | .004 | 1.56 | (1.16-2.08) | .003 |
| Disease-free survival | < .001 | 0.84 | (0.68-1.05) | .117 | 1.49 | (1.176-1.894) | .001 | 1.75 | (1.32-2.38) | < .001 |
| Relapse | .046 | 1.23 | (0.87-1.73) | .239 | 0.68 | (0.458-0.996) | .048 | 0.55 | (0.34-0.89) | .014 |
| Treatment-related mortality | .032 | 1.07 | (0.82-1.41) | .602 | 0.69 | (0.512-0.925) | .013 | 0.64 | (0.44-0.93) | .019 |
| Grade III-IV GVHD | .041 | 1.52 | (1.10-2.10) | .012 | 1.04 | (0.724-1.495) | .830 | 0.69 | (0.44-1.07) | .094 |
| Chronic GVHD | .76 | 0.92 | (0.69-1.22) | .550 | 0.93 | (0.713-1.216) | .598 | 1.01 | (0.71-1.45) | .94 |
| Outcome . | Overall P§ . | D-R group 2* vs D-R group 1† . | D-R group 3‡ vs D-R group 1 . | D-R group 3‡ vs D-R group 2 . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% confidence interval . | P . | HR . | 95% confidence interval . | P . | HR . | 95% confidence interval . | P . | ||
| Overall survival | .007 | 0.91 | (0.73-1.12) | .371 | 1.41 | (1.114-1.783) | .004 | 1.56 | (1.16-2.08) | .003 |
| Disease-free survival | < .001 | 0.84 | (0.68-1.05) | .117 | 1.49 | (1.176-1.894) | .001 | 1.75 | (1.32-2.38) | < .001 |
| Relapse | .046 | 1.23 | (0.87-1.73) | .239 | 0.68 | (0.458-0.996) | .048 | 0.55 | (0.34-0.89) | .014 |
| Treatment-related mortality | .032 | 1.07 | (0.82-1.41) | .602 | 0.69 | (0.512-0.925) | .013 | 0.64 | (0.44-0.93) | .019 |
| Grade III-IV GVHD | .041 | 1.52 | (1.10-2.10) | .012 | 1.04 | (0.724-1.495) | .830 | 0.69 | (0.44-1.07) | .094 |
| Chronic GVHD | .76 | 0.92 | (0.69-1.22) | .550 | 0.93 | (0.713-1.216) | .598 | 1.01 | (0.71-1.45) | .94 |
GVHD indicates graft-versus-host disease; and HR, hazard ratio.
D-R group 2 consists of high donor CCR5 expression and low recipient CCR5 expression.
D-R group 1 consists of donors and recipients both expressing low levels of CCR5.
D-R group 3 consists of donors with low CCR5 expression and recipients with high CCR5 expression.
Two degree of freedom test; overall comparison of 3 D-R groups.